The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Polymyalgia Rheumatica — Steroid-Sparing Approach

Strategies to reduce corticosteroid dependence in elderly inflammatory syndrome.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dahiliye (İç Hastalıkları) department. Book Appointment →

What is Polymyalgia Rheumatica — Steroid-Sparing Approach?

Polymyalgia rheumatica (PMR) is a systemic inflammatory disorder of the elderly (>50 years) presenting with bilateral shoulder and pelvic-girdle pain and stiffness.

Although low-dose corticosteroids (12.5–25 mg/day prednisolone) remain the cornerstone therapy, prolonged steroid use causes diabetes, osteoporosis, fractures, hypertension and infections.

The steroid-sparing approach aims to use add-on conventional or biologic agents to reduce cumulative steroid dose, control disease activity and prevent relapses, particularly in patients with relapsing or steroid-dependent disease.

Recent evidence supports tocilizumab (anti-IL-6) and methotrexate as effective steroid-sparing agents; biologics targeting IL-6 are emerging as transformative therapy.

Symptoms

Bilateral shoulder pain and stiffness (>45 minutes morning stiffness)
Pelvic-girdle pain involving hips and proximal thighs
Neck pain and stiffness with limited rotation
Difficulty raising arms above shoulders, dressing or rising from a chair
Constitutional symptoms: fatigue, low-grade fever, weight loss, malaise
Symptoms of giant cell arteritis (15–25% overlap): new headache, jaw claudication, scalp tenderness, visual changes
Insidious onset over days to weeks, frequently bilateral and symmetric
Steroid-dependence: relapse with prednisolone tapering below 7.5–10 mg/day

Risk Factors

Age >50 years (incidence rises sharply after age 70)
Female sex (2–3× higher risk than males)
Northern European or Scandinavian ancestry
Genetic predisposition: HLA-DRB1*04 alleles
History of giant cell arteritis (PMR coexists in 40–60%)
Recent viral or environmental trigger (controversial)
Comorbid diabetes, osteoporosis or hypertension (relative contraindications to long-term steroids)
Previous corticosteroid-related adverse events

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New-onset bilateral shoulder/pelvic-girdle pain with morning stiffness in patients >50 years
  • Unable to taper prednisolone below 5–7.5 mg/day without symptom recurrence
  • Recurrent relapses requiring multiple steroid courses
  • Development of corticosteroid-related complications (hyperglycemia, osteoporotic fracture, severe infection)
  • Symptoms suggestive of giant cell arteritis (urgent evaluation)
  • Atypical features: marked weight loss, fevers >38.5 °C, focal neurological deficits, abnormal imaging — consider alternate diagnoses

Treatment Methods

01
Diagnostic workup: ESR (typically >40 mm/h, often >100), CRP elevation, normocytic anemia, mild thrombocytosis, normal CK; rheumatoid factor and anti-CCP antibody negative
02
Imaging: musculoskeletal ultrasound (subdeltoid bursitis, biceps tenosynovitis), MRI shoulder/hip if diagnosis uncertain; PET-CT may reveal large-vessel vasculitis
03
Initial therapy: prednisolone 12.5–25 mg/day with rapid clinical improvement within 1 week, then tapered: 10 mg by week 4–8, 5 mg by month 6, off therapy at 12–24 months
04
Methotrexate as steroid-sparing agent: 7.5–15 mg/week, with folic acid 5 mg/week; decreases relapse rates by 30–50% and reduces cumulative steroid dose; consider in steroid-dependent or relapsing disease
05
Tocilizumab (IL-6 inhibitor): 162 mg subcutaneously weekly or 8 mg/kg IV monthly; SEMAPHORE trial demonstrated significant steroid-sparing effect and reduced relapses; preferred in refractory or steroid-intolerant disease
06
Sarilumab (IL-6 inhibitor): 200 mg subcutaneously every 2 weeks; SAPHYR trial demonstrated efficacy and steroid-sparing in PMR
07
Leflunomide: 10–20 mg/day; off-label use as alternative to methotrexate in patients intolerant or with contraindication; case series show modest efficacy
08
TNF inhibitors (etanercept, infliximab, adalimumab): not recommended; failed in PMR clinical trials and not indicated
09
Hydroxychloroquine: 200–400 mg/day; modest data, may be considered in mild relapsing disease as adjunct
10
Steroid-tapering protocol: BSR/BHPR guidelines recommend reduction by 2.5 mg/month until 10 mg, then 1 mg/month thereafter; slower taper if previous relapses
11
Bone health: calcium 1000 mg/day plus vitamin D 800–1000 IU/day, bisphosphonate (alendronate or risedronate) for prednisolone >5 mg/day for >3 months in higher-risk patients
12
Glucose monitoring: HbA1c at baseline and quarterly during steroid therapy; lifestyle and pharmacological treatment for steroid-induced diabetes
13
Cardiovascular risk: blood-pressure control, lipid management, low-dose aspirin for those with concomitant GCA
14
Infection prophylaxis: pneumococcal and annual influenza vaccinations, herpes zoster vaccine prior to biologics, hepatitis B/C and TB screening before tocilizumab
15
Monitoring on tocilizumab: complete blood count, lipid profile, LFTs at 4–8 weeks, then every 3 months; watch for diverticulitis and bowel perforation in patients with prior GI disease
16
Long-term outcomes: 30–50% achieve sustained remission within 1 year; 50–70% require steroid therapy >2 years; cumulative steroid burden directly correlates with adverse events
17
Multidisciplinary follow-up: rheumatology, primary care, endocrinology and ophthalmology (for GCA-related visual complications); patient education on relapse symptoms and steroid management

Which Department to Visit?

You can visit our Dahiliye (İç Hastalıkları) department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dahiliye (İç Hastalıkları) Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.